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Paeonol is an active component of Moutan Cortex Radicis and is widely used as an analgesic, antipyretic, and anti-inﬂammatory
agent in traditional Chinese medicine. We wanted to determine the role of paeonol in treating adult respiratory distress syndrome
(ARDS). We established an acute lung injury (ALI) model in Sprague-Dawley rats, which was similar to ARDS in humans, using
intratracheal administration of lipopolysaccharide (LPS). The intraperitoneal administration of paeonol successfully reduced
histopathological scores and attenuated myeloperoxidase-reactive cells as an index of polymorphonuclear neutrophils inﬁltration
and also reduces inducible nitric oxide synthase expression in the lung tissue, at 16h after LPS administration. In addition,
paeonol reduced proinﬂammatory cytokines in bronchoalveolar lavage ﬂuid, including tumor-necrosis factor-α, interleukin-
1β, interleukin-6, and plasminogen-activated inhibition factor-1. These results indicated that paeonol successfully attenuates
inﬂammatory and coagulation reactions to protect against ALI.
1.Introduction
Acute lung injury (ALI) and acute respiratory distress syn-
drome(ARDS)areinitiatedeitherbydirectinjurytothelung
or by a systemic inﬂammatory process. Both conditions are
characterized by serial pulmonary inﬂammatory responses
of the alveolar-capillary membrane. These responses include
polymorphonuclear neutrophils (PMN) accumulation [1,
2], disruption of epithelial integrity, interstitial edema,
and leakage of large amounts of protein into the alveolar
space [3, 4]. Previous research has used animal models
to study the pathophysiologic mechanism of ARDS. The
in vivo intratracheal (IT) administration of lipopolysaccha-
ride (LPS) has been widely accepted as a clinically relevant
animal model of ALI/ARDS [5–7]. The molecular events
observed after LPS-induced ALI are local recruitment and
activationofPMN[1];releaseofproinﬂammatorycytokines,
such as tumor necrosis factor (TNF)-α, Interleukine (IL)-1β,
and IL-6 [8]; the formation of reactive oxygen and nitrogen
species [9, 10]. Upregulation of inducible nitric oxide
synthase(iNOS)thatincreasednitricoxide(NO)production
plays an important role in mediating lung inﬂammation, a
factthathasbeenwellestablishedinbothanimalmodelsand
humans [11–14]. In addition, activated PMN contributes2 Evidence-Based Complementary and Alternative Medicine
to an increase in protease activity (such as myeloperoxidase
(MPO) and lysozyme activity) and promotes the formation
of various oxygen metabolites, ﬁnally leading to diﬀused
alveolar matrix damage [2, 15].
High levels of proinﬂammatory cytokines such as TNF-
α,I L - 1 β, and IL-6 are released, leading to an inﬂammatory
cascade and triggering pulmonary coagulopathy at the same
time [5, 16, 17]. These proinﬂammatory cytokines may
activate the coagulation cascade by stimulating tissue factor
(TF) expression and attenuating ﬁbrinolysis by stimulating
the release of plasminogen activators inhibitors (PAI). The
ﬁnal stage is ﬁbrin deposition in the airspaces and lung
microvasculature [16, 18–21]. Studies regarding pulmonary
manifestations in patients suﬀering from ARDS have found
e n h a n c e de x p r e s s i o no fT F ,f a c t o rV I I a( F V I I a ) ,a n dT F -
dependent factor X (FX) in bronchoalveolar lavage ﬂuid
(BALF) [22–25]. In a large multicenter study, higher levels of
PAI-1 (the hallmark of impaired ﬁbrinolysis) showed a syn-
ergistic association with ALI/ARDS, resulting in higher mor-
tality rates among such patients [26]. Recently, researchers
have become increasingly interested in the interplay between
coagulation and inﬂammation in ALI/ARDS. Pulmonary
coagulopathyisnowacceptedasanewtargetinthetreatment
of ALI/ARDS [16, 27].
Moutan cortex Radicis (MC), the root cortex of
Paeonia suﬀruticosa Andrews, is widely used as an anal-
gesic, antipyretic, and anti-inﬂammatory agent in tradi-
tional Chinese medicine (TCM) [28, 29]. According to
ancient Chinese medicine, this herb is used to regulate
human sickness such as eliminating heat, promoting blood
ﬂow, and removing blood stasis. Paeonol (20-hydroxy-
40-methoxyacetophenone), a major phenolic component
of MC, improves blood circulation through its inhibitory
eﬀects on both platelet aggregation and blood coagula-
tion [30, 31]. Research also indicated that paeonol could
inhibit the expression of cell-surface adhesion molecules
[32], proinﬂammatory cytokines such as TNF-α and IL-
1β [33, 34], and iNOS-mediated NO [35]a n dr e a c t i v e
oxygen species production [34, 35]. In addition, paeonol
inhibits the generation of proinﬂammatory cytokine, and
increases the production of IL-10 in carrageenan-evoked
thermalhyperalgesiarats[36].However,theeﬀectofpaeonol
treatmentonproinﬂammatorycytokines(TNF-α,IL-1β,and
IL-6), iNOS-mediated NO, and illness severity had not been
studied in the LPS-induced ALI rat model prior to our
research. Furthermore, we wanted to investigate the eﬀect
of paeonol regarding anticoagulation and antiﬁbrinolysis
after LPS challenge. We studied the eﬀects of paeonol using
intraperitoneal(IP)injectioninanexperimentalratmodelof
ALI (induced by IT instillation of LPS) in vivo and attempted
to clarify the mechanism involved.
2.MaterialsandMethods
2.1. Preparation of Paeonol from MC. The source of paeonol
isolated from the root bark of Paeonia suﬀruticosa and
extractedwith 95% ethanol (1:10, w/v)at 50 ◦Ca sd e s c ri bed
Hsieh et al. (2006) [34].
2.2. Establishment of LPS-Induced ALI Animal Model. This
study used pathogen-free, adult male Sprague-Dawley (SD)
rats, weighing around 250 to 300g each. The rats were
housed in standard iron cages with a twelve-hour light/dark
cycle in the animal facility of Taichung Veterans General
Hospital (TCVGH). The animal experiments were approved
by the Animal Study Protocol Review Board of TCVGH and
were conducted according to the principles stated in the
“Guide for the Care and Use of Laboratory Animals.”
The body weight and rectal temperature (RT) of the
rats were checked before the LPS challenge was introduced
(0h).Theratswerethenlightlyanesthetizedwithinhaled2%
isoﬂurane (Halocarbon Laboratories Div Halocarbon Prod-
ucts Crop, River Edge, NJ, USA) in 0.5L/min O2,1 6m g / k g
LPS (Escherichia coli 055: B5; Sigma Chemical Co., St Louis,
MO, USA), and 0.5mL of phosphate buﬀer saline (PBS).
Thismixturewasdeliveredintothelungsoftheexperimental
rats by a Micro-Sprayer and Laryngoscope (Penn-Century,
Philadelphia, PA, USA) as previously described [37, 38]. An
equal volume of PBS alone was used for the control group.
After IT instillation, the rat was placed in a vertical position
and rotated for 30s to let the instillation distribute evenly
throughout the lungs. Sixteen hours after inoculation, the
rats’ RT was measured again, and they were then killed with
CO2 asphyxiation, as described in our pilot study.
2.3. Grouping. A total of 30 SD rats were randomized on
a daily basis to a PBS control group or a treatment group.
Treatment groups received paeonol resolved in DMSO. The
eﬀective dosage of paeonol resolved in DMSO was tested in
the range of 10mg/kg to 50mg/kg, according to guidelines
presented in previous literature [32, 34, 39–41]. The double
dose of the eﬀective dosage was also tested to investigate the
dosageeﬀectiveness.AllagentswereadministeredinIPbolus
injections under light sedation with 2% isoﬂurane within
10min after instillation of LPS. Control group rats (LPS-
DMSO) received IP administered with the same volume of
DMSO. In contrast, the control group (PBS-DMSO) was IT
challenged with a PBS solution lacking LPS. At 16h after
inoculation, all rats were sacriﬁced with CO2 asphyxiation,
and their lungs were removed.
In summary, the rats were randomly divided into ﬁve
groups comprising 6 rats each, as follows
(1) PBS-DMSOgroup:IT-challengedPBSandIPDMSO,
(2) PBS-paeonol group: IT PBS and IP paeonol
25mg/kg,
(3) LPS-DMSO group: IT LPS and IP DMSO,
(4) LPS-paeonol-25 group: IT LPS and IP paeonol
25mg/kg, and
(5) LPS-paeonol-50 group: IT LPS and IP paeonol
50mg/kg.
2.4. Assessment of Histopathological Changes in LPS-Induced
ALI Rats. The right lung of the rat was ﬁxed with 10%
paraformaldehyde by trachea infusion and embedded with
paraﬃn. Hematoxylin and eosin (H&E) staining was con-
ducted with 4μm tissue slides. The lung injury was assessedEvidence-Based Complementary and Alternative Medicine 3
with the modiﬁed scoring system described by Kristof et al.
[13]. In short, two pulmonologists, who were blind to the
treatment, randomly selected 10 ﬁelds of lung sections from
3 lobes of right lung tissue per rat and read and scored
the damaged levels according to the presence and extent of
interstitial cellular inﬁltration, alveolar protein exudation,
and tissue hemorrhage by using microscope at 200x magni-
ﬁcation. Normal presentation in each category was scored as
0, and the most severe damaged in each category was scored
as 3. If the alveolar space is full with inﬂammatory cells (such
as neutrophils and macrophages), it is denoted as grade 3.
Grade 1 reﬂects just a few inﬂammatory cell inﬁltrated. [Less
thanhalfofthealveoliareﬁlleddenotesasgrade2].Similarly,
the extent of pulmonary inﬁltration of protein exudation
(reddish-stained) and alveolar hemorrhage in the lung is
determined by this way. The sum of each category from
10 diﬀerent microscopic ﬁelds is denoted as ﬁnal damaged
score in a rat. The total lung injury score of each rat was
determined as the sum of three individual scores of alveolar
cellularity, protein exudation, and tissue hemorrhage. If the
interpretations of the two physicians are quite diﬀerent, the
slides will be checked by a pathologist.
2.5. Measurement of MPO Activity. The level of lung MPO,
a marker of neutrophil inﬁltration [2, 15], was measured.
Right lung tissue (1gm) was homogenized in 1.5∼4.0 N-
ethylmaleimide (Sigma) for 30s on ice, and the homogenate
was centrifuged at 12,000g for 30min at 4◦C. The pellet
was re-suspended in 4mL of potassium phosphate buﬀer
(50mM pH 6.0) with 0.5% hexadecyltrimethylammonium
bromide (HTAB). The sample was sonicated for 30∼90s
on ice once more. The sample was then incubated at 60◦C
for 2h to deactivate tissue MPO inhibitor and then was
centrifuged at 12,000g for 10min. The supernatant ﬂuids
containing MPO were incubated in a 50mM potassium
phosphate buﬀer (KH2PO4,p H6 . 0 )b u ﬀer containing the
substrate H2O2 (1.5M) and o-dianisidine dihydrochloride
(167mg/mL; Sigma-Aldrich, USA) for 30min. The enzy-
matic activity was determined spectrophotometrically by
measuring the change in absorbance at 460nm by using a
96-well plate reader.
2.6. Western Blot for the Measurement iNOS. Frozen right
lung samples were defrosted and were homogenized with
lysisbuﬀer(RIPAwithproteaseinhibitor,witharatiooflung
tissue/lysisbuﬀerequalto100mg/400mL).Thehomogenate
wassonicatedandcentrifugedat12,000×gfor30minat4 ◦C.
The supernatant was collected, and its protein concentration
was measured by conducting Bradford protein assay (Bio-
Rad, Hercules, CA, USA). Aliquots (40μg) of protein from
each lung tissue supernatant were electrophoresed on a
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (7%) for 3h at 100V. The protein samples were
transferred onto a nitrocellulose membrane (Amersham,
USA). The membrane was then probed with polyclonal rab-
bitanti-mouseiNOSantibody(1:500dilution,GTX213110-
01, GeneTex, CA, USA) at 4◦C overnight, with appropriate
secondary antibodies. After three washes with TPBS, blots
enhanced with brown color indicated the expression of
iNOS.
2.7. Cell Counting and Measurement of Protein, Pro-
Inﬂammatory Cytokines, and Thrombin-Anti-Thrombin
Complexes (TATC), Plasminogen Activator Inhibitor (PAI-1)
in BALF in LPS-Induced ALI Rats. The right main bronchus
was ligated, and then a cannula was inserted into the
left lung through the left main bronchus. The BALF was
obtained with three aliquots of 8mL sterile saline instilled
up to a total volume of 24mL, and withdrawn three times
each, with ﬁnal ﬂuid recovery being around 20mL. The
BALF from each animal was recovered and was then passed
through a mesh (200μm) to remove the mucus, followed
by centrifugation (1500×g, 4◦C) for 15min. The sediment
cells were resuspended in 2mL PBS. Erythrocytes were
lysed using cold water and a hypertonic recovery solution
(10x HBSS). The erythrocyte-free cell suspension was then
washed once by 1x PBS and was used for total cell count.
Finally, 2 × 105 BALF-derived cells were evenly distributed
onto a slide by cytospin and then stained with Liu’s stain
for 2min, before the neutrophils were counted under the
microscope.
The resulting supernatants were stored at −70◦C until
the analysis stage. Cell counts and protein concentration
were measured by Bradford protein assay (Bio-Rad, Her-
cules, CA, USA).
The proinﬂammatory cytokines in the BALF, such as
TNF-α (BMS622MST, BenderMedsystem), IL-1β (BMS630,
BenderMedsystem),IL-6(BMS625MST,BenderMedsystem),
and IL10 (14-8101-62, eBioscience), were measured using
commercially available ELISA and in accordance with the
manufacturer’s protocol (Assay Designs, Inc. MI, USA).
Speciﬁcally, this entailed pipetting the samples of BALF
supernatant (100μL) and the standards into the cytokine
antibody precoated microplate wells. The plates were tapped
gently to mix the contents and incubated at 37◦C for 60min.
The contents of the wells were removed, and the wells were
washed three times with 400μL of wash solution. Human
cytokine antibodies (100μL) were added into each well and
incubated at 37◦C for 60min. We emptied the contents
of the wells and again applied 400μLo fw a s hs o l u t i o n
to every well three times. Horseradish peroxidase (100μL)
was added to conjugate the human cytokine antibody. After
incubation at 37◦C for 30min, 100μLo fS u b s t r a t eS o l u t i o n
TMB (tetramethylbenzidine) was added into each well for
15min at room temperature.
Color development was stopped by adding Stop Solution
(100μL, 1N solution of hydrochloric acid in water). Col-
orimetric determination was read at absorbance of 450nm
(MicroplateReaderBIO-RADLaboratories,CA,USA).Serial
dilution of each original recombination human cytokine was
performed to draw a standard curve with linear range from
0 to 500pg/mL. Concentrations of BALF cytokines were
measuredbycomparingtheabsorbanceofthestandards,and
expressed as picograms per milliliter (pg/mL).
TATC was used as a measured of coagulation through
the tissue factor pathway; high TATC level reﬂects the4 Evidence-Based Complementary and Alternative Medicine
∗
(a) PBS-DMSO
∗
(b) PBS-paeonol
∗
(c) LPS-DMSO
∗
(d) LPS-DMSO
∗
500 μm
(e) LPS- paeonol-25
∗
(f) LPS- paeonol-50
Figure 1: Eﬀects of paeonol on LPS-induced histopathological damage in rats. Histopathological damage developed 16h after intratracheal
administration of LPS (16mg/kg). The alveolar spaces (∗) are ﬁlled with a mixed mononuclear/neutrophilic inﬁltrate (), red blood cells
(⇒), and protein exudation. The alveolar walls (→) are thickened and edematous. Note the presence of cellular debris and proteinaceous
material in the air spaces in the lung tissue of the LPS-DMSO group (c) with 200x; (d) with 400x. No prominent neutrophil inﬁltration, red
blood cells or protein exudates were seen in the PBS-DMSO group (a) and PBS-paeonol group (b). The inﬁltration of neutrophil, red blood
cells and protein exudation was reduced in the LPS-paeonol-25 group (e) and LPS-paeonol-50 group (f).
activation of the coagulation system [42, 43]. TATC was
measured using the TATC enzyme-linked immunosorbent
assay Micrognost kit, in accordance with the manufacturer’s
instructions (Assay Max human thrombin-antithrombin
TAT complex ELISA kit, ET1020-1 Lot no. 1259916R1).
The level of PAI-1 antigen in BALF was measured by Rat
PAI-1 total antigen assay ELISA kit (Catalog no. RPAIKT-
TOT, Molecular Innovations, MI, USA) according to the
manufacturer’s instructions.
2.8.MeasurementofLungWeightGain(LWG)inLPS-Induced
ALIRats. Theother24SDratsweredividedintofourgroups
o f6r a t sa sf o l l o w s :
(1) PBS-DMSO group,
(2) PBS-Paeonol group,
(3) LPS-DMSO group, and
(4) LPS-Paeonol-50 group.Evidence-Based Complementary and Alternative Medicine 5
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Figure2:Eﬀectofpaeonolonrectaltemperature(RT)changesafter
LPS-inducedacutelunginjuryinrats.InthePBS-DMSOgroup,RT
was greater at 16h than at 0h; in the LPS-DMSO group, RT was
lower at 16h than at 0h. ∗P<0.05 compared with 0h. #P<0.05
compared with 16h.
The LPS-induced ALI animal model was the same as
described above. At 16h after inoculation, all rats were
sacriﬁced with CO2 asphyxiation. The total lung (including
bilateral trachea) was separated from the chest cavity of the
rat, and the body ﬂuid coating the removed lung was wiped
gently. The bilateral main bronchus was cut from the hilum
area. The residual whole lung was placed on silver paper on
an electronic scale, and the weight was recorded as whole
lung weight (WLW). The whole lung on the silver paper was
placed into an oven at 60◦C for 48h. Then the sample was
taken out of the oven and weighed again on an electronic
scale, with the weight being recorded as dry lung weight
(DLW). The WLW minus the DLW indicated the net lung
weight gain (LWG). LWG reﬂected the net lung edema status
after manipulation [44].
2.9. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n±
SEM, using the data from at 6 rats except iNOS (n = 4).
Statistical analysis of the data was conducted using Prism
3.02 software (GraphicPad Software Inc. CA, USA), via one-
way ANOVA for multiple comparisons (post hoc Tukey test).
ResultswithP<0.05wereconsideredstatisticallysigniﬁcant.
3. Results
3.1. Eﬀects of Paeonol on Histopathological Changes of Lung in
LPS-Induced ALI Rats. In the PBS-DMSO and PBS-paeonol
groups, the alveolar space was not prominent ﬂuid, protein
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Figure 3: Eﬀect of paeonol on myeloperoxidase (MPO) activity in
LPS-inducedacutelunginjuryinrats.TheMPOactivitywassimilar
between PBS-DMSO and PBS-paeonol groups (P>0.05), whereas
the MPO activity was lower in the LPS-paeonol-25 and in the LPS-
paeonol-50 groups than LPS-DMSO group. #P<0.05 compared
with LPS-DMSO.
accumulation, and the inﬁltration of inﬂammatory cells and
red blood cells (Figures 1(a) and 1(b)). In contrast, the
alveolar spaced presented with ﬂuid and protein accumu-
lation, large amounts of inﬂammatory cells, and red blood
cell inﬁltration at 16h after LPS IT instillation (16mg/kg)
(Figures 1(c) and 1(d)). Paeonol treatment with 25mg/kg
or 50mg/kg, administered after the LPS challenge, markedly
attenuated inﬂammatory cell inﬁltration and alveolar wall
thickening and diminished alveolar hemorrhage and edema
(Figures 1(e) and 1(f)). A semiquantitative analysis of the
histopathological scores of the rats’ lungs is presented in
Table 1.
3.2.EﬀectsofPaeonolonRTinLPS-InducedALIRats. TheRT
in the LPS-DMSO group at 16h after IT administration was
lower than at baseline (0h), with the diﬀerence being sta-
tistically signiﬁcant (P<0.05) (Figure 2). In contrast, for
the PBS-paeonol and LPS-paeonol-50 groups, the RT at 16h
was similar to the baseline temperature (both P>0.05)
(Figure 2). The RT in the PBS-DMSO group at 16h after
IT administration was higher than at baseline (P<0.05)
(Figure 3).
3.3. Eﬀect of Paeonol on MPO Activity and iNOS Expression.
The MPO activity of lung tissue was greater in the LPS-
DMSO, LPS-paeonol-25, and LPS-Paeonol-50 groups rel-
ative to the PBS-DMSO and PBS-paeonol groups, at 16h
after IT administration (all P<0.05) (Figure 3). The MPO
activity of lung tissue was lower in the LPS-paeonol-25 and6 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of paeonol on the histopathological scores in lipopolysaccharide-induced acute lung injury.
Cellularity Protein exudation Hemorrhage Scores
PBS-DMSO 7.2 ±1.03 .8 ±0.68 .1 ±1.81 9 .0 ±2.5
PBS-paeonol 4.5 ±0.22 .7 ±0.67 .8 ±0.71 4 .9 ±1.2
LPS-DMSO 18.0 ±0.71 0 .9 ±0.81 6 .4 ±1.04 5 .4 ±1.0
LPS-paeonol-25 10.8 ±0.9# 4.5 ±0.8# 11.5 ±1.52 6 .8 ±2.4#
LPS-paeonol-50 9.1 ±1.2# 4.1 ±0.4# 10.5 ±1.5# 23.7 ±2.9#
Data are presented as mean ± SEM; PBS-DMSO: PBS-DMSO group; PBS-paeonol: PBS-paeonol group; LPS-DMSO: LPS-DMSO group; LPS-paeonol-25:
LPS-paeonol-25mg/kg group; LPS-paeonol-50: LPS-paeonol-50mg/kg group; #P<0.05 compared with LPS-DMSO; n = 6.
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Figure 4: Eﬀect of paeonol on inducible nitric oxide synthase
(iNOS) activity in LPS-induced acute lung injury rats. The iNOS
expression was similar between PBS-DMSO and PBS-paeonol
groups (P>0.05), whereas the iNOS expression was lower in
the LPS-paeonol-50 groups than LPS-DMSO group. #P<0.05
compared with LPS-DMSO.
LPS-paeonol-50 groups relative to the LPS-DMSO group, at
16h after IT administration (both P<0.05) (Figure 3).
The iNOS expression of lung tissue was greater in the
LPS-DMSO group relative to the PBS-DMSO and PBS-
paeonolgroups,at16h(bothP<0.05)(Figure 4).TheiNOS
expression of lung tissue was lower in the LPS-paeonol-
50 group than in the LPS-DMSO group at 16h after IT
administration (P<0.05) (Figure 4).
3.4. Eﬀects of Paeonol on Leukocyte Accumulation and Protein
Exudation. The total leukocyte counts of BALF were greater
in the LPS-DMSO group relative to the PBS-DMSO and
PBS-paeonol groups, at 16h after IT administration (both
P<0.05) (Figure 5(a)). The total leukocyte counts of BALF
were lower in the PBS-paeonol-25 and PBS-paeonol-50
groups than in the LPS-DMSO group at 16h (both P<0.05)
(Figure 5(a)).
The total PMN counts of BALF were greater in the LPS-
DMSO group than in the PBS-DMSO and PBS-paeonol
groups, at 16h after IT administration (both P<0.05)
(Figure 5(b)). The total PMN counts of BALF were lower in
the LPS-paeonol-25 and LPS-paeonol 50 groups than in the
LPS-DMSO group at 16h (both P<0.05) (Figure 5(b)).
The protein concentration of BALF was greater in the
LPS-DMSO group than in the PBS-DMSO and PBS-paeonol
groups at 16h after IT administration (both P<0.05;
Figure 5(c)). The protein concentration of BALF was lower
in the LPS-paeonol-25 and in the LPS-paeonol-50 groups
than these in the LPS-DMSO group at 16h (both P<0.05;
Figure 5(c)).
3.5. Eﬀect of Paeonol on the Expression of Pro-Inﬂammatory
Cytokines of BALF. The TNF-α expression of BALF was
greater in the LPS-DMSO group than in the PBS-DMSO and
PBS-paeonol groups at 16h after IT administration (both
P<0.05) (Figure 6(a)). The TNF-α expression of BALF was
lower in the LPS-paeonol-50 group than in the LPS-DMSO
group at 16h (P<0.05) (Figure 6(a)). However, TNF-α
expression in the LPS-DMSO group was similar to that of
the LPS-paeonol-25 group (P>0.05) (Figure 6(a)).
The IL-1β expression of BALF was greater in the LPS-
DMSO group than in the PBS DMSO and PBS-paeonol
groups at 16h (both P<0.05) (Figure 6(b)). The IL-
1β expression of BALF was lower in the LPS-paeonol-25 and
the LPS-paeonol-50 groups than in the LPS-DMSO group at
16h (both P<0.05) (Figure 6(b)).
The IL-6 expression of BALF was greater in the LPS-
DMSO group than in the PBS DMSO and PBS-paeonol
groups at 16h (both P<0.05) (Figure 6(c)). The IL-6
expression of BALF was lower in the LPS-paeonol-25 and
LPS-paeonol-50 groups than in the LPS-DMSO group at
16h (both P<0.05; Figure 6(c)).
The IL-10 expression of BALF was greater in the LPS-
DMSO group than in the PBS DMSO and PBS-paeonol
groups at 16h (both P<0.05) (Figure 6(c)). The IL-10
expression of BALF was lower in the LPS-paeonol-25 and
LPS-paeonol-50 groups than in the LPS-DMSO group at
16h (both P<0.05; Figure 6(d)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀect of paeonol on leucocyte cell count and protein exudation of BALF in LPS-induced acute lung injury in rats. The total cell
count (a), neutrophil count (b), and protein exudation (c) of BALF was similar between PBS-DMSO and PBS-paeonol groups (all P>0.05),
whereas the total cell count, neutrophil count, and protein exudation of BALF was lower in the LPS-paeonol-25 and in the LPS-paeonol-50
groups than LPS-DMSO group. #P<0.05 compared with LPS-DMSO.
3.6. Eﬀect of Paeonol on the TATC and PAI-1 Concentration
of BALF in LPS-Induced ALI Rats. The TATC concentration
of BALF in the LPS-DMSO group was similar to that of
the PBS-DMSO and PBS-paeonol groups at 16h after IT
administration (both P>0.05) (Figure 7(a)).
The TATC concentration of BALF in the LPS-DMSO
group was also similar to that of the LPS-paeonol-25 and
LPS-paeonol-50groupsat16h(bothP>0.05)(Figure 7(a)).
The PAI-1 concentration of BALF was greater in the
LPS-DMSO group than in the PBS-DMSO and PBS-paeonol8 Evidence-Based Complementary and Alternative Medicine
P
B
S
-
D
M
S
O
P
B
S
-
p
a
e
o
n
o
l
L
P
S
-
D
M
S
O
L
P
S
-
p
a
e
o
n
o
l
-
2
5
L
P
S
-
p
a
e
o
n
o
l
-
5
0
P>0.05
P>0.05
#
0
200
400
600
800
T
N
F
-
α
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
/
m
L
)
(a)
P
B
S
-
D
M
S
O
P
B
S
-
p
a
e
o
n
o
l
L
P
S
-
D
M
S
O
L
P
S
-
p
a
e
o
n
o
l
-
2
5
L
P
S
-
p
a
e
o
n
o
l
-
5
0
P>0.05
#
#
0
500
1000
1500
2000
I
L
-
1
β
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
/
m
L
)
(b)
P
B
S
-
D
M
S
O
P
B
S
-
p
a
e
o
n
o
l
L
P
S
-
D
M
S
O
L
P
S
-
p
a
e
o
n
o
l
-
2
5
L
P
S
-
p
a
e
o
n
o
l
-
5
0
P>0.05
#
#
0
200
400
600
800
I
L
-
6
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
/
m
L
)
(c)
P
B
S
-
D
M
S
O
P
B
S
-
p
a
e
o
n
o
l
L
P
S
-
D
M
S
O
L
P
S
-
p
a
e
o
n
o
l
-
2
5
L
P
S
-
p
a
e
o
n
o
l
-
5
0
P>0.05
#
#
0
20
40
60
I
L
-
1
0
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
/
m
L
)
(d)
Figure 6: Eﬀect of paeonol on tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, and IL-10 concentrations of BALF in LPS-
induced acute lung injury in rats. The concentrations of TNF-α (a), IL-1β (b), IL-6 (c), and IL-10 of BALF were similar between PBS-DMSO
a n dP B S - p a e o n o lgr o u p( a l lP>0.05), whereas the concentrations of TNF-α,I L - 1 β, IL-6, and IL-10 of BALF were lower in the LPS-paeonol-
25 and in the LPS-paeonol-50 groups than LPS-DMSO group. #P<0.05 compared with LPS-DMSO.
groups at 16h (both P<0.05) (Figure 7(b)). The PAI-1
concentration of BALF was lower in the LPS-paeonol-25 and
LPS-paeonol-50 groups than in the LPS-DMSO groups at
16h (both P<0.05) (Figure 7(b)).
3.7. Eﬀects of Paeonol on LWG in LPS-Induced ALI Rats.
Lung weight gain was greater in the LPS-DMSO and LPS-
paeonol-50groupscomparedtothePBS-DMSOgroup(both
P<0.05) at 16h after LPS IT administration (Figure 8). The
LWG in the PBS-paeonol and LPS-paeonol-50 groups was
lower than that of the LPS-DMSO group (both P<0.05)
(Figure 8).
4. Discussion
Our results indicated that paeonol attenuated histopatho-
logical damage scores in the LPS-induced ALI rat model.
Paeonol reduced the activity of MPO and the expressionEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Eﬀect of paeonol on thrombin-anti-thrombin complexes (TATC) and plasminogen activator inhibitor (PAI-1) of BALF in LPS-
induced acute lung injury in rats. The concentrations of TATC in BALF were similar between PBS-DMSO and PBS-paeonol groups (P>
0.05), between LPS-DMSO and LPS-paeonol-25 groups (P>0.05), and between LPS-DMSO and LPS-paeonol-50 groups (P>0.05) (a);
The PAI-1 was similar between PBS-DMSO and PBS-paeonol groups (P>0.05), whereas the PAI-1 was lower in the LPS-paeonol-25 and in
the LPS-paeonol-50 groups than LPS-DMSO group. #P<0.05 compared with LPS-DMSO.
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Figure 8: Eﬀect of paeonol on lung weight gain (LWG) in LPS-
induced acute lung injury in rats. The LWG was similar between
PBS-DMSO and PBS-paeonol groups (P>0.05), whereas the LWG
was lower in the LPS-paeonol-50 groups than LPS-DMSO group.
#P<0.05 compared with LPS-DMSO.
of iNOS, and the concentration of PAI-1 in lung tissue,
and also reduced LWG. In addition, Paeonol reduced TNF-
α,I L - 1 β, IL-6, and PAI-1 concentrations in the BALF.
Therefore, we suggest that paeonol protects the lung in LPS-
induced ALI rats, and that the eﬀect occurs through the anti-
inﬂammation and anti-coagulation properties of paeonol.
MPOactivityisamarkerofPMNneutrophil[2,15],whereas
iNOS increases NO production and mediates lung inﬂam-
mation [11–14]. The proinﬂammatory cytokines TNF-α,I L -
1β, and IL-6 mediate the inﬂammatory cascade [8, 9, 12, 45].
PAI-1 may represent an activation of ﬁbrinolysis [18, 21, 46].
In addition, we used paeonol 25mg/kg and 50mg/kg in the
present study, if paeonol 100mg/kg such as Du et al. (2010)
[47] whether or not produce greater anti-inﬂammatory and
anti-coagulative eﬀects need further study.
Our results remain one question unanswered that is
the levels of IL-10, is an anti-inﬂammatory cytokine, were
lower in the LPS-paeonol-25 and LPS-paeonol-50 groups
than these in the LPS-DMSO group were seemly contrast to
the results of Chou (2003) [36]. One possible explanation
was that the levels of IL-10 reached a peak at 16–24h
[48], whereas the IL-10 was measured at 16h after LPS
administration, therefore, the maximal levels could not
obtain in the present study. This explanation needs further
study.
Several animal models have been developed to mimic
the pathophysiology of ALI-following LPS exposure [5–7].
In the present study, we have produced a constant and
reproducible rat model to investigate the treatment eﬀects
of paeonol in ALI by delivering LPS directly into airway in
our laboratory [37, 38]. The pulmonary histopathological
changes of LPS-induced ALI are characterized by PMN
accumulation, disruption of epithelial integrity, interstitial
edema, and leakage of a large amount of protein into
the alveolar spaces [1–4]. The results of the present study
indicated that paeonol treatment may reduce the drop in RT,
which typically follows LPS challenge. Hypothermia may be10 Evidence-Based Complementary and Alternative Medicine
an early phenomenon of sepsis; thus, paeonol might play
a critical role in preventing sepsis. In contrast, LWG may
indicate the degree of lung edema, which Paeonol may also
help reduce in the LPS-induced ALI model.
It has been well documented in both animal models and
humans that LPS stimulates iNOS expression and NO over-
production, which damages lung tissue via peroxynitrite
formation [12, 14, 46, 49, 50]. One recent report showed
that paeonol inhibits LPS-induced iNOS expression through
deactivating the mitogen-activated protein kinase (MAPK)
in RAW 264.7 macrophage-like cells [35]. However, the
eﬀect of paeonol in the ALI rat model remains unclear.
In this study, we demonstrated that paeonol signiﬁcantly
attenuates iNOS expression after a rat has been exposed
to LPS challenge, suggesting that one anti-inﬂammatory
mechanism of paeonol protects the lung from damage.
High levels of proinﬂammatory cytokines such as TNF-
α,I L - 1 β, and IL-6 play a central role in the initiation and
propagation of the inﬂammatory cascade [8, 9, 12, 45]. A
large amount of PMN is recruited from peripheral blood
into the lung, producing large amounts of MPO and reactive
oxygen derivatives. The result is a cascade-like response, and
tissue damage [2, 15, 49, 51]. In line with these theories,
we found that after instilling LPS by IT, large amounts
of proinﬂammatory cytokines were expressed in the BALF
in rat lung parenchyma, with enhanced activity of MPO.
Paeonol IP injections signiﬁcantly suppressed the expression
of TNF-α,I L - 1 β, and IL-6 in rat BALF; this also reduced
LPS-induced pulmonary parenchymal MPO activity. As
expected the number of PMNs in BALF had decreased 16h
after treatment, suggesting a mechanism by which paeonol
attenuates the LPS-induced ALI model.
The hallmark of ALI is the deposition of ﬁbrin and
platelet plugs, which induce the occlusion of microvascu-
lature of the alveolar space [3, 52]. As excessive ﬁbrin is
deposited within the airways, neutrophils and ﬁbroblasts
may further be activated. This situation compromises gas
exchange and pulmonary endothelial integrity, decreases
alveolar ﬂuid clearance, and ﬁnally leads to pulmonary
microcirculation damage and death [16, 52, 53].
Pulmonary coagulopathy is now accepted as a target
in therapeutic studies of acute lung injury or pneumonia
[16–18, 21, 27]. The available data suggest that high levels
of proinﬂammatory cytokines (such as TNF, IL-1, and IL-
6) may activate the coagulation cascade by stimulating TF
expression. High levels of these cytokines may also attenuate
ﬁbrinolysisbystimulatingthereleaseofPAI[16,18–21].Our
data showed no signiﬁcant diﬀerence in TATC level of BALF
after paeonol treatment. However, the PAI-1 levels in BALF
were signiﬁcantly decreased in the paeonol treatment group,
suggesting a strong anti-ﬁbrinolytic eﬀect of paeonol in ALI-
induced coagulopathy. Since proinﬂammatory cytokines
s e r v ea sp o t e n tr e g u l a t o r so fm a c r o p h a g eP A I - 1p r o d u c t i o n
in ALI, it remains unclear whether the anti-ﬁbrinolysis eﬀect
of paeonol occur via inhibiting PAI-1 expression directly,
or is perhaps the consequence of anti-proinﬂammatory
cytokines. Further experiments are needed to clarify the
target eﬀects on cells, and the causal relationship between
anti-inﬂammation and anti-coagulation eﬀects of paeonol.
In conclusion, the results of the current study demon-
strated that paeonol protects against lung tissue damage
in the LPS-induced ALI model. This ﬁnding suggests that
these eﬀects are because of the anti-inﬂammatory and anti-
coagulant properties of paeonol. Thus paeonol may be a
potential therapeutic reagent for treating ALI in the future.
Acknowledgment
This study was supported in part by the Taiwan Department
of Health Clinical Trial and Research Center of Excellence
(DOH101-TD-B-111-004).
References
[1] M. Chignard and V. Balloy, “Neutrophil recruitment and
increased permeability during acute lung injury induced by
lipopolysaccharide,” American Journal of Physiology—Lung
Cellular and Molecular Physiology, vol. 279, no. 6, pp. L1083–
L1090, 2000.
[2] E.Abraham,“Neutrophilsandacutelunginjury,”CriticalCare
Medicine, vol. 31, no. 4, pp. S195–S199, 2003.
[3] L. B. Ware and M. A. Matthay, “The acute respiratory distress
syndrome,” The New England Journal of Medicine, vol. 342, no.
18, pp. 1334–1349, 2000.
[4] D. Dreyfuss and J. D. Ricard, “Acute lung injury and bacterial
infection,” Clinics in Chest Medicine, vol. 26, no. 1, pp. 105–
112, 2005.
[5] G. Matute-Bello, C. W. Frevert, and T. R. Martin, “Animal
models of acute lung injury,” American Journal of Physiology—
Lung Cellular and Molecular Physiology, vol. 295, no. 3, pp.
L379–L399, 2008.
[ 6 ]H .M .W a n g ,M .B o d e n s t e i n ,a n dK .M a r k s t a l l e r ,“ O v e r v i e w
of the pathology of three widely used animal models of acute
lung injury,” European Surgical Research,v o l .4 0 ,n o .4 ,p p .
305–316, 2008.
[7] H. P. M. Van Helden, W. C. Kuijpers, D. Steenvoorden et al.,
“Intratracheal aerosolization of endotoxin (LPS) in the rat: a
comprehensive animal model to study adult (acute) respira-
tory distress syndrome,” Experimental Lung Research, vol. 23,
no. 4, pp. 297–316, 1997.
[8] T. Shinbori, H. Walczak, and P. H. Krammer, “Activated
T killer cells induce apoptosis in lung epithelial cells and
the release of pro-inﬂammatory cytokine TNF-α,” European
Journal of Immunology, vol. 34, no. 6, pp. 1762–1770, 2004.
[9] E. A. Williams, G. J. Quinlan, P. B. Anning, P. Goldstraw, and
T. W. Evans, “Lung injury following pulmonary resection in
the isolated, blood- perfused rat lung,” European Respiratory
Journal, vol. 14, no. 4, pp. 745–750, 1999.
[10] M. A. Matthay, T. Geiser, S. Matalon, and H. Ischiropoulos,
“Oxidant-mediated lung injury in the acute respiratory dis-
tress syndrome,” Critical Care Medicine, vol. 27, no. 9, pp.
2028–2030, 1999.
[11] P.Enkhbaatar,K.Murakami,K.Shimodaetal.,“Theinducible
nitric oxide synthase inhibitor BBS-2 prevents acute lung
injury in sheep after burn and smoke inhalation injury,”
American Journal of Respiratory and Critical Care Medicine,
vol. 167, no. 7, pp. 1021–1026, 2003.
[12] A. Kobayashi, S. Hashimoto, K. Kooguchi et al., “Expression
of inducible nitric oxide synthase and inﬂammatory cytokines
in alveolar macrophages of ARDS following sepsis,” Chest, vol.
113, no. 6, pp. 1632–1639, 1998.Evidence-Based Complementary and Alternative Medicine 11
[13] A. S. Kristof, P. Goldberg, V. Laubach, and S. N. A. Hussain,
“Role of inducible nitric oxide synthase in endotoxin-induced
acute lung injury,” AmericanJournal of Respiratory and Critical
Care Medicine, vol. 158, no. 6, pp. 1883–1889, 1998.
[14] H. M. Razavi, R. Werhun, J. A. Scott et al., “Eﬀects of inhaled
nitric oxide in a mouse model of sepsis-induced acute lung
injury,” Critical Care Medicine, vol. 30, no. 4, pp. 868–873,
2002.
[15] R. L. Zemans, S. P. Colgan, and G. P. Downey, “Transepithelial
migration of neutrophils: mechanisms and implications for
acute lung injury,” American Journal of Respiratory Cell and
Molecular Biology, vol. 40, no. 5, pp. 519–535, 2009.
[16] M. J. Schultz, J. J. Haitsma, H. Zhang, and A. S. Slutsky,
“Pulmonary coagulopathy as a new target in therapeutic
studies of acute lung injury or pneumonia—a review,” Critical
Care Medicine, vol. 34, no. 3, pp. 871–877, 2006.
[17] M. Levi and H. Ten Cate, “Disseminated intravascular coagu-
lation,” The New England Journal of Medicine, vol. 341, no. 8,
pp. 586–592, 1999.
[18] E. Abraham, “Coagulation abnormalities in acute lung injury
and sepsis,” American Journal of Respiratory Cell and Molecular
Biology, vol. 22, no. 4, pp. 401–404, 2000.
[19] J .A.Bastarache,L.B.W are,andG.R.Bernard,“Theroleofthe
coagulation cascade in the continuum of sepsis and acute lung
injury and acute respiratory distress syndrome,” Seminars in
Respiratory and Critical Care Medicine, vol. 27, no. 4, pp. 365–
376, 2006.
[20] L. B. Ware, J. A. Bastarache, and L. Wang, “Coagulation and
ﬁbrinolysis in human acute lung injury—new therapeutic
targets?” The Keio Journal of Medicine, vol. 54, no. 3, pp. 142–
149, 2005.
[21] M. Wygrecka, E. Jablonska, A. Guenther, K. T. Preissner,
and P. Markart, “Current view on alveolar coagulation and
ﬁbrinolysisinacuteinﬂammatoryandchronicinterstitiallung
diseases,” Thrombosis and Haemostasis, vol. 99, no. 3, pp. 494–
501, 2008.
[22] A. W. Rijneveld, S. Weijer, P. Bresser et al., “Local activation
of the tissue factor-factor VIIa pathway in patients with
pneumonia and the eﬀect of inhibition of this pathway in
murine pneumococcal pneumonia,” Critical Care Medicine,
vol. 34, no. 6, pp. 1725–1730, 2006.
[23] M. J. Schultz, J. Millo, M. Levi et al., “Local activation of
coagulation and inhibition of ﬁbrinolysis in the lung during
ventilator associated pneumonia,” Thorax,v o l .5 9 ,n o .2 ,p p .
130–135, 2004.
[24] T. Fuchs-Buder, P. De Moerloose, B. Ricou et al., “Time course
of procoagulant activity and D dimer in bronchoalveolar
ﬂuid of patients at risk for or with acute respiratory distress
syndrome,” American Journal of Respiratory and Critical Care
Medicine, vol. 153, no. 1, pp. 163–167, 1996.
[25] S. Idell, K. B. Koenig, D. S. Fair, T. R. Martin, J. McLarty,
and R. J. Maunder, “Serial abnormalities of ﬁbrin turnover
in evolving adult respiratory distress syndrome,” American
JournalofPhysiology—LungCellularandMolecularPhysiology,
vol. 261, no. 4, part 1, pp. L240–L248, 1991.
[26] L. B. Ware, M. A. Matthay, P. E. Parsons et al., “Patho-
genetic and prognostic signiﬁcance of altered coagulation
and ﬁbrinolysis in acute lung injury/acute respiratory distress
syndrome,” Critical Care Medicine, vol. 35, no. 8, pp. 1821–
1828, 2007.
[ 2 7 ]L .B .W a r e ,E .C a m e r e r ,K .W e l t y - W o l f ,M .J .S c h u l t z ,a n d
M. A. Matthay, “Bench to bedside: targeting coagulation
and ﬁbrinolysis in acute lung injury,” American Journal of
Physiology—Lung Cellular and Molecular Physiology, vol. 291,
no. 3, pp. L307–L311, 2006.
[28] H. C. Lin, H. Y. Ding, F. N. Ko, C. M. Teng, and Y. C. Wu,
“Aggregation inhibitory activity of minor acetophenones from
Paeonia species,” Planta Medica, vol. 65, no. 7, pp. 595–599,
1999.
[29] S. Tatsumi, T. Mabuchi, T. Abe, L. Xu, T. Minami, and S.
Ito, “Analgesic eﬀect of extracts of Chinese medicinal herbs
Moutan cortex and Coicis semen on neuropathic pain in
mice,” Neuroscience Letters, vol. 370, no. 2-3, pp. 130–134,
2004.
[30] Y. K. Koo, J. M. Kim, J. Y. Koo et al., “Platelet anti-aggregatory
and blood anti-coagulant eﬀects of compounds isolated from
Paeonia lactiﬂora and Paeonia suﬀruticosa,” Pharmazie, vol.
65, no. 8, pp. 624–628, 2010.
[31] A. Hirai, T. Terano, and T. Hamazaki, “Studies on the
mechanism of antiaggregatory eﬀect of Moutan Cortex,”
Thrombosis Research, vol. 31, no. 1, pp. 29–40, 1983.
[32] I. T. Nizamutdinova, H. M. Oh, Y. N. Min et al., “Paeonol
suppresses intercellular adhesion molecule-1 expression in
t u m o rn e c r o s i sf a c t o r - α-stimulated human umbilical vein
endothelial cells by blocking p38, ERK and nuclear factor-κB
signaling pathways,” International Immunopharmacology, vol.
7, no. 3, pp. 343–350, 2007.
[33] L. L. Pan and M. Dai, “Paeonol from Paeonia suﬀruticosa
prevents TNF-α-induced monocytic cell adhesion to rat aortic
endothelial cells by suppression of VCAM-1 expression,”
Phytomedicine, vol. 16, no. 11, pp. 1027–1032, 2009.
[34] C. L. Hsieh, C. Y. Cheng, T. H. Tsai et al., “Paeonol
reduced cerebral infarction involving the superoxide anion
andmicrogliaactivationinischemia-reperfusioninjuredrats,”
Journal of Ethnopharmacology, vol. 106, no. 2, pp. 208–215,
2006.
[35] H. S. Chae, O. H. Kang, Y. S. Lee et al., “Inhibition of LPS-
inducediNOS,COX-2andinﬂammatorymediatorexpression
by paeonol through the MAPKs inactivation in RAW 264.7
cells,” American Journal of Chinese Medicine,v o l .3 7 ,n o .1 ,p p .
181–194, 2009.
[36] T. C. Chou, “Anti-inﬂammatory and analgesic eﬀects of
paeonol in carrageenan-evoked thermal hyperalgesia,” British
Journal of Pharmacology, vol. 139, no. 6, pp. 1146–1152, 2003.
[37] C. L. Wu, L. Y. Lin, H. M. Yeh, M. C. Chan, C. H. Yang, and C.
M.Hsueh,“DelayofLPS-inducedacutelunginjuryresolution
by soluble immune complexes is neutrophil dependent,”
Shock, vol. 32, no. 3, pp. 276–285, 2009.
[38] C. L. Wu, L. Y. Lin, J. S. Yang, M. C. Chan, and C. M. Hsueh,
“Attenuation of lipopolysaccharide-induced acute lung injury
by treatment with IL-10,” Respirology, vol. 14, no. 4, pp. 511–
521, 2009.
[39] H. Li, M. Dai, and W. Jia, “Paeonol attenuates high-fat-
diet-induced atherosclerosis in rabbits by anti-inﬂammatory
activity,” Planta Medica, vol. 75, no. 1, pp. 7–11, 2009.
[40] K. Ishiguro, T. Ando, O. Maeda et al., “Paeonol attenuates
TNBS-induced colitis by inhibiting NF-κB and STAT1 trans-
activation,”Toxicology andAppliedPharmacology, vol. 217, no.
1, pp. 35–42, 2006.
[41] S. H. Kim, S. A. Kim, M. K. Park et al., “Paeonol inhibits
anaphylactic reaction by regulating histamine and TNF-α,”
InternationalImmunopharmacology,vol.4,no.2,pp.279–287,
2004.
[42] S. Weijer, S. H. H. F. Schoenmakers, S. Florcpin et al.,
“Inhibition of the tissue factor/factor VIIa pathway does
not inﬂuence the inﬂammatory or antibacterial response to12 Evidence-Based Complementary and Alternative Medicine
abdominal sepsis induced by Escherichia coli in mice,” Journal
of Infectious Diseases, vol. 189, no. 12, pp. 2308–2317, 2004.
[ 4 3 ]S .H .S l o f s t r a ,A .P .G r o o t ,N .A .M a r i s ,P .H .R e i t s m a ,H .
Ten Cate, and C. A. Spek, “Inhalation of activated protein C
inhibits endotoxin-induced pulmonary inﬂammation in mice
independent of neutrophil recruitment,” British Journal of
Pharmacology, vol. 149, no. 6, pp. 740–746, 2006.
[ 4 4 ] C .H .C h u ,D .D a v i dL i u ,Y .H .H s u ,K .C .L e e ,a n dH .I .C h e n ,
“Propofol exerts protective eﬀects on the acute lung injury
induced by endotoxin in rats,” Pulmonary Pharmacology and
Therapeutics, vol. 20, no. 5, pp. 503–512, 2007.
[45] R. M. Strieter and S. L. Kunkel, “Acute lung injury: the
role of cytokines in the elicitation of neutrophils,” Journal of
Investigative Medicine, vol. 42, no. 4, pp. 640–651, 1994.
[46] C. F. Su, F. L. Yang, and H. I. Chen, “Inhibition of inducible
nitric oxide synthase attenuates acute endotoxin-induced lung
injury in rats,” Clinical and Experimental Pharmacology and
Physiology, vol. 34, no. 4, pp. 339–346, 2007.
[ 4 7 ]Q .D u ,G .Z .F e n g ,L .S h e n ,J .C u i ,a n dJ .K .C a i ,“ P a e o n o l
attenuates airway inﬂammation and hyperresponsiveness in
a murine model of ovalbumin-induced asthma,” Canadian
Journal of Physiology and Pharmacology, vol. 88, no. 10, pp.
1010–1016, 2010.
[48] C. L. Wu, L. Y. Lin, J. S. Yang, M. C. Chan, and C. M. Hsueh,
“Attenuation of lipopolysaccharide-induced acute lung injury
by treatment with IL-10,” Respirology, vol. 14, no. 4, pp. 511–
521, 2009.
[49] H. M. Razavi, F. W. Le, S. Weicker et al., “Pulmonary
neutrophilinﬁltrationinmurinesepsis:roleofinduciblenitric
oxide synthase,” American Journal of Respiratory and Critical
Care Medicine, vol. 170, no. 3, pp. 227–233, 2004.
[ 5 0 ] D .W a n g ,J .W e i ,K .H s ue ta l . ,“ E ﬀects of nitric oxide synthase
inhibitors on systemic hypotension, cytokines and inducible
nitric oxide synthase expression and lung injury following
endotoxin administration in rats,” Journal of Biomedical
Science, vol. 6, no. 1, pp. 28–35, 1999.
[51] E. Abraham, A. Carmody, R. Shenkar, and J. Arcaroli,
“Neutrophils as early immunologic eﬀectors in hemorrhage-
or endotoxemia-induced acute lung injury,” American Journal
of Physiology—Lung Cellular and Molecular Physiology, vol.
279, no. 6, pp. L1137–L1145, 2000.
[52] A. G¨ unther, P. Mosavi, S. Heinemann et al., “Alveolar ﬁbrin
formation caused by enhanced procoagulant and depressed
ﬁbrinolytic capacities in severe pneumonia: comparison with
the acute respiratory distress syndrome,” American Journal of
Respiratory and Critical Care Medicine, vol. 161, no. 2 I, pp.
454–462, 2000.
[53] A. Sapru, J. L. Wiemels, J. S. Witte, L. B. Ware, and M. A.
Matthay, “Acute lung injury and the coagulation pathway:
potential role of gene polymorphisms in the protein C and
ﬁbrinolytic pathways,” Intensive Care Medicine, vol. 32, no. 9,
pp. 1293–1303, 2006.